Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc. company information, Employees & Contact Information

Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas. Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. Viridian’s goal is to advance VRDN-001 as a potential best-in-class intravenous therapy followed by VRDN-003 as a potential first- and best-in-class subcutaneous therapy for the treatment of TED. In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Looking for a particular Viridian Therapeutics, Inc. employee's phone or email?

Viridian Therapeutics, Inc. Questions

News

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Yahoo Finance

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire

Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates - Yahoo Finance

Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates Yahoo Finance

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results - Business Wire

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results Business Wire

Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments - Business Wire

Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments Business Wire

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED) - Business Wire

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED) Business Wire

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results - Business Wire

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results Business Wire

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED) - Business Wire

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED) Business Wire

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results - Business Wire

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results Business Wire

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease - Business Wire

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease Business Wire

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease - Business Wire

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease Business Wire

Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock - Business Wire

Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock Business Wire

Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million - Business Wire

Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million Business Wire

Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024 - Business Wire

Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024 Business Wire

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock - Business Wire

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock Business Wire

Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections - Yahoo Finance

Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections Yahoo Finance

Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update - Business Wire

Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update Business Wire

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease - Business Wire

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease Business Wire

Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update - Yahoo Finance

Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update Yahoo Finance

Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease - Business Wire

Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease Business Wire

Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing - Business Wire

Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing Business Wire

Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer - citybiz

Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer citybiz

Viridian Announces Positive Data from Ongoing Phase 1/2 - GlobeNewswire

Viridian Announces Positive Data from Ongoing Phase 1/2 GlobeNewswire

Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference | User | ricentral.com - FinancialContent

Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference | User | ricentral.com FinancialContent

miRagen Therapeutics Announces Company Name Change to - GlobeNewswire

miRagen Therapeutics Announces Company Name Change to GlobeNewswire

Top Viridian Therapeutics, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant